• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

心脏急症药物治疗中的药代动力学和药效学考量

Pharmacokinetic and pharmacodynamic considerations in drug therapy of cardiac emergencies.

作者信息

Pentel P, Benowitz N

出版信息

Clin Pharmacokinet. 1984 Jul-Aug;9(4):273-308. doi: 10.2165/00003088-198409040-00001.

DOI:10.2165/00003088-198409040-00001
PMID:6380870
Abstract

In the drug therapy of cardiac emergencies, it is necessary to rapidly achieve therapeutic drug concentrations and adjust drug dose as the patient's clinical status changes. Cardiac dysfunction is often present and may alter drug pharmacokinetics. Circulatory failure causes sympathetically mediated vasoconstriction in most tissues, with relative sparing of the brain and heart due to autoregulation. Blood flow to vasoconstricted tissues is reduced, and the available cardiac output is redistributed so that the heart and brain receive a greater fraction. Drug distribution to tissues is therefore slowed, and the initial concentration of drug in blood is higher when circulatory failure is present than when it is absent. This higher blood concentration is reflected by higher concentrations of drug in the brain and heart, which are relatively well perfused. Initial doses of many drugs need to be reduced in patients with circulatory failure to prevent cardiac or central nervous system toxicity. Cardiac output is markedly diminished during cardiopulmonary resuscitation (CPR), but blood flow distribution is qualitatively similar to that of circulatory failure with spontaneous circulation. Pneumatic trousers increase lower extremity vascular resistance and may produce a similar redistribution of blood flow. Drug distribution during the use of CPR or pneumatic trousers should be similar to that of circulatory failure with spontaneous circulation, but few data are available to guide drug dosing during the use of these interventions. Animal data suggest that the central volume of distribution of some drugs during CPR may be as small as one-tenth of normal. Drug metabolism in circulatory failure may be impaired by reduced hepatic blood flow resulting in decreased clearance of highly extracted drugs, or by hepatocellular dysfunction resulting in decreased clearance of poorly extracted drugs. Drug excretion may be impaired by reduced renal blood flow resulting in decreased filtration or secretion and increased reabsorption. The maintenance dose of many drugs must therefore be reduced in the presence of circulatory failure. Intravenous drug administration is preferred in patients with circulatory failure. The central intravenous route is often convenient but must be used cautiously when administering potentially cardiotoxic drugs. Intratracheal administration appears to be a promising alternative for some drugs, such as adrenaline (epinephrine). Intracardiac injections are hazardous and offer no demonstrated advantage over other routes.(ABSTRACT TRUNCATED AT 400 WORDS)

摘要

在心脏急症的药物治疗中,有必要迅速达到治疗药物浓度,并随着患者临床状况的变化调整药物剂量。心脏功能障碍常常存在,可能会改变药物的药代动力学。循环衰竭会导致大多数组织出现交感神经介导的血管收缩,由于自身调节作用,脑和心脏相对不受影响。流向血管收缩组织的血流量减少,心输出量重新分布,使得心脏和脑获得更大比例的心输出量。因此,药物向组织的分布减慢,存在循环衰竭时血液中的初始药物浓度高于不存在循环衰竭时。这种较高的血液浓度反映在灌注相对良好的脑和心脏中较高的药物浓度上。许多药物的初始剂量在循环衰竭患者中需要减少,以防止心脏或中枢神经系统毒性。心肺复苏(CPR)期间心输出量显著减少,但血流分布在性质上与有自主循环的循环衰竭相似。气动抗休克裤会增加下肢血管阻力,并可能产生类似的血流重新分布。CPR或使用气动抗休克裤期间的药物分布应与有自主循环的循环衰竭相似,但关于这些干预措施使用期间药物给药的指导数据很少。动物数据表明,CPR期间某些药物的中央分布容积可能低至正常的十分之一。循环衰竭时的药物代谢可能因肝血流量减少导致高摄取药物清除率降低而受损,或因肝细胞功能障碍导致低摄取药物清除率降低而受损。药物排泄可能因肾血流量减少导致滤过或分泌减少以及重吸收增加而受损。因此,在存在循环衰竭时,许多药物的维持剂量必须减少。循环衰竭患者首选静脉给药。中心静脉途径通常很方便,但在使用潜在心脏毒性药物时必须谨慎使用。气管内给药似乎是某些药物(如肾上腺素)的一种有前景的替代途径。心内注射有风险,且未显示出比其他途径有明显优势。(摘要截选至400字)

相似文献

1
Pharmacokinetic and pharmacodynamic considerations in drug therapy of cardiac emergencies.心脏急症药物治疗中的药代动力学和药效学考量
Clin Pharmacokinet. 1984 Jul-Aug;9(4):273-308. doi: 10.2165/00003088-198409040-00001.
2
Advances in drug therapy of cardiopulmonary arrest.心肺复苏药物治疗的进展
Clin Pharm. 1987 Feb;6(2):118-39.
3
[The effect of cardiac insufficiency on pharmacokinetics].[心脏功能不全对药代动力学的影响]
Arch Mal Coeur Vaiss. 1989 Mar;82(3):391-7.
4
Clinical pharmacokinetics of lignocaine.利多卡因的临床药代动力学。
Clin Pharmacokinet. 1978 May-Jun;3(3):177-201. doi: 10.2165/00003088-197803030-00001.
5
Pharmacokinetic and pharmacodynamic considerations when treating patients with sepsis and septic shock.治疗脓毒症和脓毒性休克患者时的药代动力学和药效学考量
Clin Pharmacokinet. 2002;41(14):1135-51. doi: 10.2165/00003088-200241140-00002.
6
[Pharmacotherapy of ventricular fibrillation. A prospective study in an emergency medical service].[心室颤动的药物治疗。在紧急医疗服务中的一项前瞻性研究]
Anaesthesist. 1991 Mar;40(3):172-9.
7
Drug therapy of cardiopulmonary resuscitation in children.儿童心肺复苏的药物治疗
Drugs. 1989 Mar;37(3):356-74. doi: 10.2165/00003495-198937030-00005.
8
Disease-induced modifications of drug pharmacokinetics.疾病引起的药物药代动力学改变。
Int J Clin Pharmacol Res. 1983;3(4):215-26.
9
Endotracheal drug therapy in cardiopulmonary resuscitation.心肺复苏中的气管内给药疗法
Clin Pharm. 1986 Jul;5(7):572-9.
10
Cardiac drugs: adjusting their use in aging patients.心脏药物:调整其在老年患者中的使用
Geriatrics. 1987 Aug;42(8):31-4, 37-40.

引用本文的文献

1
Impact of lipopolysaccharide-induced inflammation on the disposition of the aminocephalosporin cefadroxil.脂多糖诱导的炎症对氨基头孢菌素头孢羟氨苄处置的影响。
Antimicrob Agents Chemother. 2013 Dec;57(12):6171-8. doi: 10.1128/AAC.01497-13. Epub 2013 Sep 30.
2
Pharmacokinetic and pharmacodynamic considerations when treating patients with sepsis and septic shock.治疗脓毒症和脓毒性休克患者时的药代动力学和药效学考量
Clin Pharmacokinet. 2002;41(14):1135-51. doi: 10.2165/00003088-200241140-00002.
3
Pharmacokinetics and pharmacodynamics of sedatives and analgesics in the treatment of agitated critically ill patients.

本文引用的文献

1
Effect of epinephrine and norepinephrine on the electrocardiogram of 100 normal subjects.肾上腺素和去甲肾上腺素对100名正常受试者心电图的影响。
Am J Cardiol. 1960 May;5:594-603. doi: 10.1016/0002-9149(60)90124-7.
2
EFFECTS OF ATROPINE AND SCOPOLAMINE ON THE CARDIOVASCULAR SYSTEM IN MAN.阿托品和东莨菪碱对人体心血管系统的作用
Anesthesiology. 1964 Mar-Apr;25:123-30. doi: 10.1097/00000542-196403000-00003.
3
CLOSED-CHEST CARDIAC MASSAGE FOR CIRCULATORY ARREST. EFFECTIVENESS IN 100 CONSECUTIVE CASES.用于循环骤停的闭胸心脏按摩。连续100例的效果
镇静剂和镇痛药在治疗躁动危重症患者中的药代动力学和药效学
Clin Pharmacokinet. 1997 Dec;33(6):426-53. doi: 10.2165/00003088-199733060-00003.
4
Myocardial uptake of drugs and clinical effects.药物的心肌摄取与临床疗效。
Clin Pharmacokinet. 1986 Sep-Oct;11(5):354-71. doi: 10.2165/00003088-198611050-00002.
5
Clinical pharmacological and therapeutic considerations in general intensive care. A review.综合重症监护中的临床药理学与治疗学考量。综述
Drugs. 1987 Dec;34(6):662-94. doi: 10.2165/00003495-198734060-00003.
6
Pharmacokinetics and pharmacodynamics in critically ill patients.危重症患者的药代动力学和药效学
World J Surg. 1987 Apr;11(2):210-7. doi: 10.1007/BF01656404.
7
Plasma concentrations and haemodynamic effects of nimodipine in patients resuscitated after cardiac arrest.尼莫地平在心脏骤停复苏后患者中的血浆浓度及血流动力学效应
Eur J Clin Pharmacol. 1989;36(4):327-33. doi: 10.1007/BF00558290.
8
Cardiopulmonary bypass and the pharmacokinetics of drugs. An update.体外循环与药物的药代动力学。最新进展。
Clin Pharmacokinet. 1989 Jul;17(1):10-26. doi: 10.2165/00003088-198917010-00002.
9
The place of intracardiac injections in the treatment of cardiac arrest.心内注射在心脏骤停治疗中的地位。
Drugs. 1991 Dec;42(6):915-8. doi: 10.2165/00003495-199142060-00002.
Arch Intern Med. 1964 Jul;114:5-12. doi: 10.1001/archinte.1964.03860070051002.
4
Studies with tritiated digoxin in human subjects after intravenous administration.静脉注射后用氚标记地高辛对人体进行的研究。
Am Heart J. 1962 Apr;63:528-36. doi: 10.1016/0002-8703(62)90310-1.
5
Effect of atropine on the heart-rate.阿托品对心率的影响。
Lancet. 1958 Dec 20;2(7060):1313-5. doi: 10.1016/s0140-6736(58)90580-4.
6
Effect of norepinephrine uptake blockers on norepinephrine kinetics.去甲肾上腺素摄取阻滞剂对去甲肾上腺素动力学的影响。
Clin Pharmacol Ther. 1981 Jan;29(1):12-20. doi: 10.1038/clpt.1981.3.
7
Lignocaine and indocyanine green kinetics in patients following myocardial infarction.心肌梗死后患者的利多卡因和吲哚菁绿动力学
Br J Clin Pharmacol. 1980 Oct;10(4):353-61. doi: 10.1111/j.1365-2125.1980.tb01771.x.
8
Pharmacokinetics of bretylium in man after intravenous administration.静脉注射后溴苄铵在人体中的药代动力学。
J Pharmacokinet Biopharm. 1980 Aug;8(4):363-72. doi: 10.1007/BF01059384.
9
Kinetics of antifibrillatory effects of bretylium: correlation with myocardial drug concentrations.溴苄铵抗纤颤作用的动力学:与心肌药物浓度的相关性
Am J Cardiol. 1980 Oct;46(4):583-92. doi: 10.1016/0002-9149(80)90507-x.
10
Administration of heparin causes in vitro release of non-esterified fatty acids in human plasma.肝素的给药会导致人体血浆中游离脂肪酸的体外释放。
Life Sci. 1980 Sep 1;27(9):771-80. doi: 10.1016/0024-3205(80)90331-8.